How Long Can You Live With a Lung Transplant?

Median survival after a lung transplant currently stands at about six years, which lags behind most other solid organ transplants but represents a significant improvement over earlier decades of the procedure.¹ That number, however, is an average that flattens a wide range of individual outcomes. Some recipients live well beyond fifteen years, while others face life-threatening complications within the first few months. What actually determines where you fall on that spectrum involves your original lung disease, the type of surgery, how aggressively chronic rejection is managed, and even how closely you follow your medication schedule.

What the Survival Numbers Look Like at Each Milestone

The most useful way to think about lung transplant survival is not as a single number but as a series of checkpoints. Data from the international transplant registry show that after the modern lung allocation system was introduced, about 86% of recipients survive the first year, roughly 56% reach five years, and around a third make it to ten years.² Those numbers have climbed steadily. In the 1990s, five-year survival was only about 40%; by the 2000s and 2010s, it had risen to around 55%.² Improvements in surgical technique, organ preservation, and post-operative care have all contributed, though the field still acknowledges that lung transplant outcomes trail behind those for kidneys, livers, and hearts.

For older recipients, the timeline compresses. In a large registry study of more than 5,800 patients aged 65 and up, the median survival was about four and a half years. One-year survival for that group was 83%, three-year survival was 62%, and five-year survival was 45%.³ Within that older cohort, each additional step in age made a difference: those aged 65 to 69 had a median survival of about 4.6 years, while recipients 75 and older had a median of roughly three years.³

The First Year Is the Riskiest

The early post-operative period is when lung transplant recipients face the steepest danger, and the biggest early threat is called primary graft dysfunction, essentially a form of acute injury to the new lungs shortly after surgery. In patients who develop severe graft dysfunction, 30-day mortality is around 42%, compared with roughly 6% in patients who escape it.⁴ Graft dysfunction accounts for close to half of all deaths in the first month. And its effects do not end there: among recipients who survive the initial episode, the risk of death remains elevated for years afterward.⁴ The chronic inflammation triggered by early graft injury can eventually promote chronic rejection, linking the acute crisis to the most common cause of late death.⁵

Infection is the other major first-year concern. Because transplant recipients are on heavy immunosuppression, they are vulnerable to organisms that healthy immune systems handle easily. Bacterial infections dominate the earliest weeks, but as time goes on, viruses like cytomegalovirus and fungal infections become more prominent. Fungal infections are particularly feared because they carry high mortality and can damage the airways where the new lung is stitched in.⁶

Chronic Rejection and Why It Dominates the Long-Term Picture

If you survive the first year in good shape, the primary threat shifts to chronic lung allograft dysfunction, which is essentially a slow, largely irreversible decline in lung function. It is the leading cause of death beyond the first year. The umbrella term covers two main patterns. The more common one, bronchiolitis obliterans syndrome, involves progressive airway narrowing. The less common but more aggressive pattern, restrictive allograft syndrome, involves scarring that stiffens the entire lung.⁷

The distinction between these two patterns matters for prognosis. In one study of 468 transplant recipients, about 30% of those who developed chronic rejection had the restrictive form, and their survival was markedly worse: a median of about 18 months from the onset of chronic rejection, compared with roughly four years for those with the obstructive pattern.⁸ In patients with advanced chronic rejection, those with the restrictive or mixed pattern faced substantially higher mortality risk, and rapid disease progression was particularly deadly.⁹

What drives chronic rejection? Part of the answer involves antibodies the recipient’s immune system creates against the donated lung. When these donor-specific antibodies persist rather than appear briefly and fade, the risk of chronic rejection climbs sharply. One study found that five-year freedom from chronic rejection was only about 56% in patients with persistent antibodies versus 77% in those whose antibodies were transient.¹⁰ Early detection and treatment of these antibodies, before overt rejection develops, can cut the risk of chronic rejection or death by about two-thirds.¹¹ This is one of the clearest examples of how vigilant monitoring can meaningfully extend survival.

How Your Original Disease Shapes the Outcome

Not everyone who gets a lung transplant starts from the same place, and the disease that destroyed the original lungs has a surprisingly strong influence on how long the new ones last. Among ten-year survivors reviewed in one large study, the breakdown by diagnosis was about 30% chronic obstructive pulmonary disease (COPD), 20% cystic fibrosis, and 11% pulmonary fibrosis.¹² That does not mean COPD patients inherently do better; COPD is simply the most common transplant indication, so more COPD patients appear in every survival category.

When researchers compare survival rates head to head, the picture gets more nuanced. Cystic fibrosis patients who test negative for certain dangerous bacteria before transplant tend to do well, with five- and ten-year survival around 76% and 52% respectively. Patients transplanted for primary pulmonary hypertension also tend toward longer survival, with about 59% reaching ten years. Pulmonary fibrosis patients fare less well, with ten-year survival around 24%.¹³ Cystic fibrosis patients who carry certain bacterial infections before surgery, particularly Burkholderia cepacia, have dramatically worse outcomes, with only about 15% surviving to ten years.¹³

Single Versus Double Lung Transplant

Whether you receive one new lung or two affects long-term survival, though the difference does not show up immediately. In a propensity-matched analysis of older adults, single and double lung transplants had nearly identical outcomes at 30 days and one year. But by five years, double lung recipients pulled ahead: about 53% survived versus 45% with a single lung.¹⁴ Receiving a single lung was independently associated with higher five-year mortality. The reasons likely involve the remaining native lung becoming a source of infection or other problems over time, and the double transplant simply providing more functional reserve.

That said, the decision is not always straightforward. Some patients are too sick to tolerate the longer surgery required for a double transplant, and some diseases are traditionally treated with a single lung because it works well enough in the short term. The trade-off between short-term surgical risk and long-term survival benefit is something transplant teams weigh on a case-by-case basis.

Does Donor Age Matter?

You might assume that younger donor lungs automatically mean better outcomes, but the research paints a more complicated picture. Multiple studies have found that the interaction between donor and recipient age matters more than donor age alone. Older donor lungs did not negatively affect survival in older recipients, but they did limit outcomes in younger ones.¹⁵ A European study reached similar conclusions: donor age category did not significantly alter one- or five-year survival in either young or older recipients, though young recipients who received older donor lungs did face a higher risk of severe graft dysfunction early on.¹⁶

An additional propensity-matched analysis confirmed that even when older donors were paired with recipients aged 60 to 69, no survival differences emerged after adjusting for other variables.¹⁷ The practical takeaway is that rejecting otherwise healthy lungs solely because the donor was older can mean a longer and potentially fatal wait on the transplant list, especially for older recipients who can do just as well with those organs.

Living on Immunosuppression

Even when the transplanted lungs work beautifully, the medications needed to keep them working exact a toll of their own. Lifelong immunosuppression is non-negotiable, and the side effects accumulate. In one series of transplant recipients followed long-term, kidney damage affected about 57%, osteoporosis about 55%, high blood pressure 45%, and diabetes about 20%.¹⁸ The kidney damage is especially troubling because it can progress to the point of needing dialysis or even a kidney transplant, creating a cascade of medical complexity.

Cancer risk also rises with long-term immunosuppression. The most characteristic malignancy is post-transplant lymphoproliferative disease, a type of lymphoma linked to Epstein-Barr virus replication that the suppressed immune system can no longer keep in check.¹⁹ Skin cancers are also common. The transplant community has been working to develop drug regimens that minimize these long-term harms without losing protection against rejection, but it remains a difficult balancing act.²⁰

Why Adherence and Rehabilitation Make a Real Difference

One of the strongest and most actionable predictors of long-term survival is something that might sound mundane: taking your medications and showing up for appointments. A study that tracked adherence over the first three years after transplant found that patients with good adherence had five-year survival of 79%, compared with 64% for those with suboptimal adherence. Rates of chronic rejection were also lower in the adherent group.²¹ That 15-percentage-point gap in survival is enormous in this field, and it is driven by behavior rather than biology.

Physical rehabilitation also plays a meaningful role. Lung transplant recipients often enter surgery deconditioned after months or years of severe lung disease. A meta-analysis found that pulmonary rehabilitation substantially improved walking distance, oxygen consumption, and muscle strength after transplant.²² While the evidence linking exercise directly to longer survival remains limited to observational data, the improvements in physical capacity and quality of life are well documented.²³ Better functional status also puts patients in a stronger position if complications arise later.

Re-Transplantation When the First Graft Fails

For recipients whose transplanted lungs eventually fail, a second transplant is sometimes an option. The raw numbers initially look discouraging: across all repeat transplant recipients, the risk of death is about 64% higher than for first-time recipients.²⁴ But that headline number is misleading, because it lumps together patients who were re-transplanted urgently in poor condition with those who were carefully selected. When researchers used propensity matching to compare similarly healthy patients, the survival difference between first and repeat transplants essentially disappeared.²⁴

Patient selection matters greatly. Re-transplantation within the first year of the original surgery, older age, poor functional status, and being critically ill at the time of re-transplant all worsen outcomes.²⁵ For patients who develop chronic rejection gradually and are still in reasonable shape, a second transplant can offer a genuine second chance with survival comparable to the first go-round.

Socioeconomic Factors and Disparities

Survival after lung transplant is not purely a medical story. Recipients from socioeconomically distressed communities have slightly lower five-year survival, roughly 56% compared with 58% in less distressed areas, and the effect persists after adjusting for clinical variables.²⁶ Racial and ethnic disparities also exist in post-transplant survival, though a large cohort study found that socioeconomic position and geography explained very little of the difference between racial groups, suggesting other systemic factors are at play.²⁷

Interestingly, one study found that formal psychosocial scoring tools used during transplant evaluation did not predict long-term survival, but practical factors like the type of caregiver and how far the patient lived from the transplant center did. Recipients whose primary caregiver was not a spouse or partner, and those living in a different region from their transplant center, had lower odds of long-term survival.²⁸ Access to consistent follow-up care appears to matter more than abstract measures of socioeconomic status.

Emerging Technologies Expanding the Donor Pool

One reason lung transplant survival has historically lagged behind other organs is that lungs are fragile and many donated lungs have been deemed too damaged to use. A technology called ex vivo lung perfusion (EVLP) is changing that equation. EVLP allows transplant teams to take marginal donor lungs, hook them up to a machine that pumps a nutrient-rich solution through them outside the body, and evaluate whether they can recover enough to be usable. This has expanded the number of available lungs and shortened wait times.

Crucially, the outcomes appear to match those of conventionally preserved lungs. A long-term study from a high-volume center found no significant difference in either chronic rejection rates or graft survival between EVLP and non-EVLP lungs out to nine years.²⁹ A population-level analysis of more than 23,000 transplant recipients confirmed that EVLP-treated lungs showed similar five-year survival.³⁰ By rescuing organs that would otherwise be discarded, EVLP helps more patients get transplanted sooner, which itself can improve outcomes by catching people before they deteriorate further on the wait list.

On the monitoring side, blood tests that measure donor-derived cell-free DNA are showing promise as a way to detect graft injury without invasive biopsies. When the transplanted lung is under immune attack, dying donor cells release fragments of their DNA into the recipient’s bloodstream, and the levels of this DNA can flag rejection episodes that may otherwise be clinically silent. Patients with persistently elevated levels had more than six times the risk of developing graft failure.³¹ The test appears to have a strong ability to rule out acute rejection when levels are low, making it a useful surveillance tool between biopsies.³² Earlier detection means earlier treatment, and earlier treatment of rejection is consistently linked to better long-term outcomes.